Precigen (PGEN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 17, 2026.
Voting matters and shareholder proposals
Election of nine directors is proposed, with all nominees recommended by the board.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) is included.
Approval sought for an amendment to the 2023 Omnibus Incentive Plan.
Proxies may vote on other business arising at the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election.
Director nominees include Randal Kirk, Cesar Alvarez, Steven Frank, Vinita Gupta, Fred Hassan, Jeffrey Kindler, Nancy Howell Agee, Helen Sabzevari, and James Turley.
Latest events from Precigen
- Shareholders will vote on director elections, auditor ratification, executive pay, and a key equity plan amendment.PGEN
Proxy filing30 Apr 2026 - PAPZIMEOS sets a new standard for RRP, fueling growth and pipeline expansion via a unique platform.PGEN
Fireside chat3 Apr 2026 - PAPZIMEOS launch accelerates revenue growth and adoption, with Q1 2026 revenue set to exceed $18M.PGEN
Q4 202525 Mar 2026 - PAPZIMEOS launch accelerates adoption and revenue, but non-cash charges drive Q3 net loss.PGEN
Q3 20253 Feb 2026 - PRGN-2012 pivotal data and focus drive new funding, but losses and going concern risks persist.PGEN
Q2 20241 Feb 2026 - 51% complete response and 86% surgery reduction with durable benefit and strong safety.PGEN
Study Result31 Jan 2026 - FDA-approved RRP therapy saw rapid US uptake, strong brand growth, and global expansion plans.PGEN
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Gene therapy for RRP shows strong efficacy, safety, and commercial promise, with BLA submission imminent.PGEN
Stifel 2024 Healthcare Conference13 Jan 2026 - Gene therapy for RRP nears FDA approval, with UltraCAR-T and global expansion advancing.PGEN
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026